Integrated Cancer Repository for Cancer Research (iCaRe2)
This observational study, called the Integrated Cancer Repository for Cancer Research (iCaRe2), is collecting health information and biological samples (like tissue or blood) from adults with or at risk for certain cancers, including pancreatic, thyroid, lung, esophageal, and thymus cancer. It also includes healthy individuals as a comparison group. The goal is to create a large resource to help researchers better understand cancer development and progression, and to design new ways to prevent, screen for, detect, and treat cancer. The study aims to develop and implement a web-based registry to manage this information.
- Study design
- This is an observational study, meaning researchers will collect information without giving any specific treatments. It aims to enroll a very large number of participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal of developing the web-based registry is measured over 86 years, suggesting a very long-term collection of data.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Integrated Cancer Repository for Cancer Research
At a glance
Conditions
Where it's being run
42 sites across 18 statesStudy leadership
- Kurt Fisher, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Nebraska
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Development and Implementation of a Web-based Cancer Collaborative Registry86 years
This is a registry that will continue to accrue participants indefinitely.